Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Gile, Jennifer , Ou, Fang‐Shu , Mahipal, Amit , Larson, Joseph J. , Mody, Kabir , Jin, Zhaohui , Hubbard, Joleen M. , Hálfdánarson, Þorvarður R. , Alberts, Steven R. , Jatoi, Aminah , Smoot, Rory L. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Gile, Jennifer Jane , Hubbard, Joleen , Halfdanarson, Thorvardur R , McWilliams, Robert R , Ma, Wen Wee , Ilyas, Sumera, Roberts, Lewis R , Borad, Mitesh J , Smoot, Rory L , Mahipal, Amit , Alberts, Steven R , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Jin, Zhaohui , McWilliams, Robert R. , Wee, Wen , Ilyas, Sumera I. , Gores, Gregory J. , Borad, Mitesh J. , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 28, 2021 | Volume: No volume available | Issue: 5 | Pages: 1228-1240

10.1200/po.21.00064 | PMID 34778691 Get It

PURPOSECholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor receptor ( FGFR) alterations, which occurs in approximately 15%-20% of intrahepatic CCAs. Herein, we describe the FGFR inhibitor (FGFRi)-associated treatment toxicity and cancer-specific outcomes from a multicenter single-institution cohort.METHODSThis is a retrospective study of patients with CCA and known FGFR alterations treated with FGFRi. We describe the toxicity and efficacy in patients treated at Mayo Clinic between January 2010 and December 2020.RESULTSOur group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi. The most common grade 1 or higher adverse events for all patients included fatigue (92%), AST elevations (78%), anemia (80%), decreased platelet count (63%), and hyperphosphatemia (74%). Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Females had significantly longer progression-free survival at 6.9 months (95% CI, 5.2 to 11.8) on FGFRi compared with males at 4.9 months (95% CI, 2.8 to not estimable; P = .038).CONCLUSIONFGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.
Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry
El‐Battrawy, Ibrahim , Cammann, Victoria L. , Szawan, Konrad A. , Vece, Davide Di , Rossi, Aurelio, Wischnewsky, Manfred , Hermes‐Laufer, Julia , Gili, Sebastiano , Citro, Rodolfo , Franke, Jennifer , Meder, Benjamin , Knorr, Maike, Heiner, Susanne, Burgdorf, Christof , Kherad, Behrouz , Tschöpe, Carsten , Sarcon, Annahita, Shinbane, Jerold S., Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Pott, Alexander , Meyer, Philippe , Arroja, José David , Banning, Adrian , Cuculi, Florim , Fischer, Thomas, Vasankari, Tuija , Napp, L. Christian , Budnik, Monika , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Chan, Christina , Bridgman, Paul , Beug, Daniel , Gilyarova, Ekaterina, Gilyarov, Mikhail , Kozel, Martin , Winchester, David E. , Ukena, Christian , Carrilho‐Ferreira, Pedro , Hauck, Christian , Paolini, Carla , Bilato, Claudio , Kobayashi, Yoshio, Rihal, Charanjit S. , Liu, Kan , Bianco, Matteo , Jörg, Lucas, Rickli, Hans , Böhm, Michael , Pinto, Fausto J. , Widimský, Petr , Felix, Stephan B. , Opolski, Grzegorz , Rottbauer, Wolfgang , Pieske, Burkert , Katus, Hugo A. , Münzel, Thomas , Crea, Filippo , Lüscher, Thomas F. , Duru, Fırat , Borggrefe, Martin, Ghadri, Jelena R. , Akın, İbrahim , Templin, Christian , Crea, Filippo , Citro, Rodolfo , El-Battrawy, Ibrahim , Duru, Firat , Tschöpe, Carsten , Koenig, Wolfgang , Meyer, Philippe , Banning, Adrian , Gilyarov, Mikhail , Ukena, Christian , Bilato, Claudio , Bianco, Matteo , Kato, Ken , Bossone, Eduardo , Neuhaus, Michael, Jaguszewski, Miłosz , Noutsias, Michel , D’Ascenzo, Fabrizio , Dichtl, Wolfgang , Kobza, Richard , Airaksinen, Juhani , Kaiser, Christoph A. , Delmas, Clément , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gałuszka, Jan , Poglajen, Gregor , Prasad, Abhiram , Rihal, Charanjit S. , Schulze, Paul Christian , Pestana, Gonçalo , Nguyen, Thanh Ha Tuan , Maier, Lars S. , Braun-Dullaeus, Ruediger Christian , Hasenfuß, Gerd , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Horowitz, John D. , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

Journal of the American Heart Association | July 28, 2021 | Volume: 10 | Issue: 15 | Pages: No page available

10.1161/jaha.119.014059 | PMID 34315238 Get It

Background Atrial fibrillation (AF) is a major risk factor for mortality. The prevalence, clinical correlates, and prognostic impact of AF in Takotsubo syndrome (TTS) have not yet been investigated in a large patient cohort. This study aimed to investigate the prevalence, clinical correlates, and prognostic impact of AF in patients with TTS. Methods and Results Patients with TTS were enrolled from the International Takotsubo Registry, which is a multinational network with 26 participating centers in Europe and the United States. Patients were dichotomized according to the presence or absence of AF at the time of admission. Of 1584 patients with TTS, 112 (7.1%) had AF. The mean age was higher ( P <0.001), and there were fewer women ( P =0.046) in the AF than in the non‐AF group. Left ventricular ejection fraction was significantly lower ( P =0.001), and cardiogenic shock was more often observed ( P <0.001) in the AF group. Both in‐hospital ( P <0.001) and long‐term mortality ( P <0.001) were higher in the AF group. Multivariable Cox regression analysis revealed that AF was independently associated with higher long‐term mortality (hazard ratio, 2.31; 95% CI, 1.50–3.55; P <0.001). Among patients with AF on admission, 42% had no known history of AF before the acute TTS event, and such patients had comparable in‐hospital and long‐term outcomes compared with those with a history of AF. Conclusions In patients presenting with TTS, AF on admission is significantly associated with increased in‐hospital and long‐term mortality rates. Whether antiarrhythmics and/or cardioversion are beneficial in TTS with AF should thus be tested in a future trial. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01947621.
Evaluating consumer and clinical sleep technologies: an American Academy of Sleep Medicine update
Schutte-Rodin, Sharon, Deak, Maryann C., Khosla, Seema, Goldstein, Cathy , Yurcheshen, Michael , Chiang, Ambrose , Gault, Dominic, Kern, Joseph, O’Hearn, Daniel J. , Ryals, Scott, Verma, Nitun, Kirsch, Douglas B. , Baron, Kelly Glazer , Holfinger, Steven , Miller, Jennifer N. , Patel, Ruchir, Bhargava, Sumit, Ramar, Kannan , Holfinger, Steven J

Mayo Clinic

Journal of Clinical Sleep Medicine | July 27, 2021 | Volume: 17 | Issue: 11 | Pages: 2275-2282

10.5664/jcsm.9580 | PMID 34314344 Get It

Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo
Goodwin, Pamela J. , Ennis, Marguerite , Chen, Bingshu E. , Parulekar, Wendy R. , Shepherd, Lois E. , Whelan, Timothy J. , Ligibel, Jennifer A. , Hershman, Dawn L. , Hobday, Timothy J. , Rastogi, Priya , Lemieux, Julie , Thompson, Alastair M. , Rea, Daniel , Ennis, Marguerite , Chen, Bingshu E , Hershman, Dawn L , Mayer, IA , Rabaglio-Poretti, Manuela , Stambolic, Vuk , Rea, Daniel W , Dowling, Ryan J.O. , Gelmon, Karen A. , Mayer, Ingrid A. , Rabaglio, Manuela , Stambolic, Vuk , Whelan, Timothy J

Mayo Clinic

JNCI Cancer Spectrum | July 26, 2021 | Volume: 5 | Issue: 5 | Pages: No page available

10.1093/jncics/pkab066 | PMID 34485814 Get It

Abstract Background Circulating levels of cancer antigen (CA) 15–3, a tumor marker and regulator of cellular metabolism, were reduced by metformin in a nonrandomized neoadjuvant study. We examined the effects of metformin (vs placebo) on CA 15–3 in participants of MA.32, a phase III randomized trial in early-stage breast cancer. Methods A total of 3649 patients with T1-3, N0-3, M0 breast cancer were randomly assigned; pretreatment and 6-month on-treatment fasting plasma were centrally assayed for CA 15–3. Genomic DNA was analyzed for the rs11212617 single nucleotide polymorphism. Absolute and relative change of CA 15–3 (metformin vs placebo) were compared using Wilcoxon rank and t tests. Regression models adjusted for baseline differences and assessed key interactions. All statistical tests were 2-sided. Results Mean (SD) age was 52.4 (10.0) years. The majority of patients had T2/3, node-positive, hormone receptor–positive, HER2-negative breast cancer treated with (neo)adjuvant chemotherapy and hormone therapy. Mean (SD) baseline CA 15–3 was 17.7 (7.6) and 18.0 (8.1 U/mL). At 6 months, CA 15–3 was statistically significantly reduced in metformin vs placebo arms (absolute geometric mean reduction in CA 15–3 = 7.7% vs 2.0%, P &lt; .001; relative metformin: placebo level of CA 15–3 [adjusted for age, baseline body mass index, and baseline CA 15–3] = 0.94, 95% confidence interval = 0.92 to 0.96). This reduction was independent of tumor characteristics, perioperative systemic therapy, baseline body mass index, insulin, and the single nucleotide polymorphism status (all Ps &gt; .11). Conclusions Our observation that metformin reduces CA 15–3 by approximately 6% was corroborated in a large placebo-controlled randomized trial. The clinical implications of this reduction in CA 15–3 will be explored in upcoming efficacy analyses of breast cancer outcomes in MA.32.
Patient Voice and Mission: Why Do Patients Choose Family Medicine and What Do They Value?
Horn, Jennifer L. , Allen, Summer V. , Boehmer, Kasey R. , Pecina, Jennifer L. , Horn, Jennifer, Pecina, Jennifer

Mayo Clinic

Journal of Patient Experience | July 26, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/23743735211034037 | PMID 34368431 Get It

Known gaps exist between what patients value and institutions prioritize. We sought to incorporate patients’ reasons for valuing family medicine into a new Mission and Vision statement by deploying brief surveys to a convenience sample of patients. We conducted descriptive quantitative analyses of demographics and inductive content analysis of written responses. Patients returned 92 (20%) of 450 questionnaires. Responders were 63% female, mean age of 47 years. Patients noted distinguishing features of family medicine were (1) continuity of care, (2) all-encompassing care, and (3) trusted referrals. Some patients reported not knowing there was a distinction between family medicine and other primary care.
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Drayman, Nir , DeMarco, Jennifer K. , Jones, Krysten A. , Azizi, Saara‐Anne , Froggatt, Heather M. , Tan, Kemin , Maltseva, N. , Chen, Siquan, Nicolaescu, Vlad , Dvorkin, Steve, Furlong, Kevin, Firpo, Mason R. , Mastrodomenico, Vincent , Bruce, Emily A. , Schmidt, Madaline M. , Jedrzejczak, R. , Schuster, Brooke , Nair, Vishnu , Han, Kyu‐Yeon , O’Brien, Amornrat , Τοματσίδου, Αναστασία, Vignuzzi, Marco , Botten, Jason , Brooke, Christopher B. , Lee, Hyun , Severson, William E., Palmer, Kenneth E. , Dickinson, Bryan C. , Joachimiak, A. , Randall, Glenn , Tay, Savaş , Maltseva, Natalia Ivanovna , Kathayat, Rahul S , Bruce, Emily A , Schmidt, Madaline M , Jedrzejczak, Robert , Muñoz-Alía, Miguel Á , Schuster, Brooke , Nair, Vishnu , Han, Kyu-Yeon , Meyer, Bjoern , Vignuzzi, Marco , Botten, Jason W , Brooke, Christopher B , Lee, Hyun , Baker, Susan C , Mounce, Bryan C , Heaton, Nicholas S , Dickinson, Bryan C , Joachimiak, Andrzej , Randall, Glenn , Tay, Savaş , Furlong, Kevin, Muñoz-Alía, Miguel Ángel , Missiakas, Dominique M.

Mayo Clinic

Science | July 20, 2021 | Volume: 373 | Issue: 6557 | Pages: 931-936

10.1126/science.abg5827 | PMID 34285133 Get It

Targeting the main protease of SARS-CoV-2 Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
Ganesh, Ravindra , Bierle, Dennis M. , Anderson, Ryan J. , Arndt, Lori L., Arndt, Richard , Culbertson, Tracy L, Borgen, Molly J. Destro, Hanson, Sara N. , Kennedy, Brian , Kottke, Brian B, Larsen, Jennifer J., Ramar, Priya , Rosedahl, Jordan K., Seville, Maria Teresa , Speicher, Leigh L. , Tulledge‐Scheitel, Sidna M. , Wilker, Caroline G. , Arndt, Richard F, Destro Borgen, Molly J, Kennedy, Brian D, Tulledge-Scheitel, Sidna M, Razonable, Raymund R , Ganesh, Ravindra , Philpot, Lindsey M. , Razonable, Raymund R.

Mayo Clinic

The Journal of Infectious Diseases | July 17, 2021 | Volume: 224 | Issue: 8 | Pages: 1278-1286

10.1093/infdis/jiab377 | PMID 34279629 Get It

Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes of patients who received these therapies to identify factors associated with hospitalization and other clinical outcomes. Methods Adult patients who received monoclonal antibody from 19 November 2020 to 11 February 2021 were selected and divided into those who received bamlanivimab (n = 2747) and casirivimab-imdevimab (n = 849). The 28-day all-cause and COVID-19–related hospitalizations were compared between the groups. Results The population included 3596 patients; the median age was 62 years, and 50% were female. All had ≥1 medical comorbidity; 55% had multiple comorbidities. All-cause and COVID-19–related hospitalization rates at 28 days were 3.98% and 2.56%, respectively. After adjusting for medical comorbidities, there was no significant difference in all-cause and COVID-19–related hospitalization rates between bamlanivimab and casirivimab-imdevimab (adjusted hazard ratios [95% confidence interval], 1.4 [.9–2.2] and 1.6 [.8–2.7], respectively). Chronic kidney, respiratory and cardiovascular diseases, and immunocompromised status were associated with higher likelihood of hospitalization. Conclusions This observational study on the use of bamlanivimab and casirivimab-imdevimab in high-risk patients showed similarly low rates of hospitalization. The number and type of medical comorbidities are associated with hospitalizations after monoclonal antibody treatment.
EBV‐positive HIV‐associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features
Chapman, Jennifer R. , Bouska, Alyssa , Zhang, Weiwei , Alderuccio, Juan Pablo , Lossos, Izidore S. , Rimsza, Lisa M. , Maguire, Alanna , Yi, Shuhua , Chan, Wing C. , Song, Joo Y. , Maguire, Alanna , Rimsza, Lisa M , Song, Joo Y , Bouska, Alyssa , Vega, Francisco , Maguire, Alanna

Mayo Clinic

British Journal of Haematology | July 17, 2021 | Volume: 194 | Issue: 5 | Pages: 870-878

10.1111/bjh.17708 | PMID 34272731 Get It

Summary Even in the era of highly active combination antiretroviral therapy (cART), patients with HIV have a disproportionate risk of developing aggressive lymphomas that are frequently Epstein‐Barr virus (EBV)‐related. Here, we investigate HIV‐associated diffuse large B‐cell lymphoma (HIV‐DLBCL) and compare EBV‐positive and EBV‐negative cases. HIV‐DLBCL were identified from two academic medical centres and characterised by immunohistochemistry, EBV status, fluorescence in situ hybridisation, cell of origin determination by gene expression profiling, and targeted deep sequencing using a custom mutation panel of 334 genes. We also applied the Lymphgen tool to determine the genetic subtype of each case. Thirty HIV‐DLBCL were identified, with a median patient age of 46 years and male predominance (5:1). Thirteen cases (48%) were EBV‐positive and 14 (52%) EBV‐negative. Nine of the 16 tested cases (56%) had MYC rearrangement, three (19%) had BCL6 (two of which were double hit MYC / BCL6 ) and none had BCL2 rearrangements. Using the Lymphgen tool, half of the cases (15) were classified as other. All HIV‐DLBCL showed mutational abnormalities, the most frequent being TP53 (37%), MYC (30%), STAT3 (27%), HIST1H1E (23%), EP300 (20%), TET2 (20%), SOCS1 (17%) and SGK1 (17%). EBV‐negative cases were mostly of germinal centre B‐cell (GCB) origin (62%), showed more frequent mutations per case (a median of 13·5/case) and significant enrichment of TP53 (57% vs. 15%; P = 0·046), SGK1 (36% vs. 0%; P = 0·04), EP300 (43% vs. 0%; P = 0·02) and histone‐modifying gene (e.g. HIST1H1E , HIST1H1D , 79% vs. 31%; P = 0·02) mutations. EBV‐positive cases were mostly of non‐GCB origin (70%), with fewer mutations per case (median 8/case; P = 0·007), and these tumours were enriched for STAT3 mutations ( P = 0·10). EBV‐positive cases had a higher frequency of MYC mutations but the difference was not significant (36% vs. 15%; P = 0·38). EBV‐association was more frequent in HIV‐DLBCLs, arising in patients with lower CD4 counts at diagnosis (median 46·5 vs. 101, P = 0·018). In the era of cART, approximately half of HIV‐DLBCL are EBV‐related. HIV‐DLBCL are enriched for MYC rearrangements, MYC mutations and generally lack BCL2 rearrangements, regardless of EBV status. Among HIV‐DLBCL, tumours that are EBV‐negative and EBV‐positive appear to have important differences, the latter arising in context of lower CD4 count, showing frequent non‐GCB origin, lower mutation burden and recurrent STAT3 mutations.
Civilian walking blood bank emergency preparedness plan
Holcomb, John B. , Spinella, Philip C. , Apelseth, Torunn Oveland , Butler, Frank K., Cannon, Jeremy W. , Cap, Andrew P., Corley, Jason B., Doughty, Heidi , Fitzpatrick, Michael H., Goldkind, Sara F., Gurney, Jennifer M. , Homer, Mary J. , Jenkins, Donald H. , Moore, Eugene, Ness, Paul M., Schreiber, Martin A. , Shinar, Eilat , Sloan, Steve, Stubbs, James R. , Taylor, Audra L., Ward, Kevin R. , Waltman, Elizabeth, Yazer, Mark H. , Jansen, Jan O , Strandenes, Geir , Stubbs, James R , Yazer, Mark , Spinella, Philip C , Apelseth, Torunn , Holcomb, John B , Cap, Andrew P., Ilstrup, Sarah J. , Jansen, Jan O. , Marques, Marisa B. , O’Connor, Kevin C. , Strandenes, Geir

Mayo Clinic

Transfusion | July 16, 2021 | Volume: 61 | Issue: S1 | Pages: No page available

10.1111/trf.16458 | PMID 34269450 Get It

Abstract Background The current global pandemic has created unprecedented challenges in the blood supply network. Given the recent shortages, there must be a civilian plan for massively bleeding patients when there are no blood products on the shelf. Recognizing that the time to death in bleeding patients is less than 2 h, timely resupply from unaffected locations is not possible. One solution is to transfuse emergency untested whole blood (EUWB), similar to the extensive military experience fine‐tuned over the last 19 years. While this concept is anathema in current civilian transfusion practice, it seems prudent to have a vetted plan in place. Methods and Materials During the early stages of the 2020 global pandemic, a multidisciplinary and international group of clinicians with broad experience in transfusion medicine communicated routinely. The result is a planning document that provides both background information and a high‐level guide on how to emergently deliver EUWB for patients who would otherwise die of hemorrhage. Results and Conclusions Similar plans have been utilized in remote locations, both on the battlefield and in civilian practice. The proposed recommendations are designed to provide high‐level guidance for experienced blood bankers, transfusion experts, clinicians, and health authorities. Like with all emergency preparedness, it is always better to have a well‐thought‐out and trained plan in place, rather than trying to develop a hasty plan in the midst of a disaster. We need to prevent the potential for empty shelves and bleeding patients dying for lack of blood.
Coronavirus disease 2019 in children
Levy, Emily R. , Blumenthal, Jennifer , Levy, Emily R , Chiotos, Kathleen

Mayo Clinic

Current Opinion in Infectious Diseases | July 15, 2021 | Volume: 34 | Issue: 5 | Pages: 500-509

10.1097/qco.0000000000000762 | PMID 34261902 Get It

Purpose of review Over the course of the coronavirus disease 2019 (COVID-19) pandemic, it has become clear that the clinical features, epidemiology, and outcomes of COVID-19 are distinct in children relative to adults. In this review, we will present recent pediatric studies informing our current understanding of COVID-19 in children, and review pediatric considerations surrounding disease transmission, currently available therapies, and vaccination. Recent findings Recent studies have shed light on the clinical epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children, identifying a high prevalence of asymptomatic and mild infections, with severe COVID-19 infrequently reported. Several adult clinical trials have informed the use of remdesivir, anti-SARS-CoV-2 monoclonal antibodies, dexamethasone, and tocilizumab in the management of COVID-19. Associations between underlying comorbid medical conditions and severe outcomes, as well as transmission dynamics of SARS-CoV-2 in children, are complex and warrant further study. Finally, highly efficacious vaccines are available for adults and adolescents, with pediatric trials ongoing. Summary Children generally fare well with acute COVID-19 infection, though critical illness is possible. Future research should focus on clarifying the role of children in SARS-CoV-2 transmission and optimal prevention strategies, particularly in the school setting, as well as evaluating pediatric vaccine candidates.